SCHEMBL1542708

SCHEMBL1542708

COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C1(C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
HPGD P15428 4/20 0.43
MAPK10 P53779 1/20 0.43
CDK9 P50750 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ABL1 P00519 1/20 0.37
MAPK14 Q16539 1/20 0.37
F10 P00742 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542369 0.84 CYP3A4 (0.65) CYP3A4HPGDMAPK10CDK9SMN1; SMN2
SCHEMBL1542544 0.82 CYP3A4 (0.57) CYP3A4HPGDMAPK10CDK9SMN1; SMN2
SCHEMBL1542623 0.79 CYP3A4 (0.72) CYP3A4HPGDCDK9SMN1; SMN2ALDH1A1
SCHEMBL724765 0.78 CYP3A4 (0.75) CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2126941 0.76 CYP3A4 (0.53) CYP3A4HPGDMAPK10ALDH1A1MAPK1
SCHEMBL2129460 0.75 CYP3A4 (0.59) CYP3A4HPGDMAPK10ALDH1A1MAPK1
SCHEMBL2691615 0.75 CYP3A4 (0.48) CYP3A4MAPK10PIK3CDPIK3CAPIK3CB
SCHEMBL2127123 0.75 CYP3A4 (0.70) CYP3A4CDK9PIK3CDPIK3CAPIK3CB
SCHEMBL1542598 0.75 CYP3A4 (0.70) CYP3A4CDK9PIK3CDPIK3CAPIK3CB
SCHEMBL2127061 0.74 CYP3A4 (0.53) CYP3A4HPGDCDK9SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885HPGD 2497/4885MAPK10 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.